<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Biotherapy</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Biotherapy</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский биотерапевтический журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-9784</issn><issn publication-format="electronic">1726-9792</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1327</article-id><article-id pub-id-type="doi">10.17650/1726-9784-2022-21-2-47-55</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL REPORTS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Influence of gender and age of patients with oral mucosa cancer on the phenotype of systemic and local immunity</article-title><trans-title-group xml:lang="ru"><trans-title>Влияние пола и возраста больных раком слизистой оболочки полости рта на фенотип системного и локального иммунитета</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7631-5699</contrib-id><name-alternatives><name xml:lang="en"><surname>Zabotina</surname><given-names>T. N.</given-names></name><name xml:lang="ru"><surname>Заботина</surname><given-names>Т. Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Tatiana Nicolaevna Zabotina</p><p>24 Kashirskoe Shosse, Moscow 115478</p></bio><bio xml:lang="ru"><p>Татьяна Николаевна Заботина</p><p>115478 Москва, Каширское шоссе, 24</p></bio><email>tatzabotina@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9146-5986</contrib-id><name-alternatives><name xml:lang="en"><surname>Chertkova</surname><given-names>A. I.</given-names></name><name xml:lang="ru"><surname>Черткова</surname><given-names>А. И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Antonina I. Chertkova</p><p>24 Kashirskoe Shosse, Moscow 115478</p></bio><bio xml:lang="ru"><p>115478 Москва, Каширское шоссе, 24</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1854-3455</contrib-id><name-alternatives><name xml:lang="en"><surname>Borunova</surname><given-names>A. A.</given-names></name><name xml:lang="ru"><surname>Борунова</surname><given-names>А. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Anna A. Borunova</p><p>24 Kashirskoe Shosse, Moscow 115478</p></bio><bio xml:lang="ru"><p>115478 Москва, Каширское шоссе, 24</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2790-6673</contrib-id><name-alternatives><name xml:lang="en"><surname>Zakharova</surname><given-names>E. N.</given-names></name><name xml:lang="ru"><surname>Захарова</surname><given-names>Е. Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Elena N. Zakharova</p><p>24 Kashirskoe Shosse, Moscow 115478</p></bio><bio xml:lang="ru"><p>115478 Москва, Каширское шоссе, 24</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3937-474X</contrib-id><name-alternatives><name xml:lang="en"><surname>Shoua</surname><given-names>E. K.</given-names></name><name xml:lang="ru"><surname>Шоуа</surname><given-names>Э. К.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Esma K. Shoua</p><p>24 Kashirskoe Shosse, Moscow 115478</p></bio><bio xml:lang="ru"><p>115478 Москва, Каширское шоссе, 24</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9488-4710</contrib-id><name-alternatives><name xml:lang="en"><surname>Shoua</surname><given-names>I. B.</given-names></name><name xml:lang="ru"><surname>Шоуа</surname><given-names>И. Б.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Ilona B. Shoua</p><p>24 Kashirskoe Shosse, Moscow 115478</p></bio><bio xml:lang="ru"><p>115478 Москва, Каширское шоссе, 24</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3090-695X</contrib-id><name-alternatives><name xml:lang="en"><surname>Tsiklauri</surname><given-names>V. T.</given-names></name><name xml:lang="ru"><surname>Циклаури</surname><given-names>В. Т.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Vasily T. Tsiklauri</p><p>24 Kashirskoe Shosse, Moscow 115478</p></bio><bio xml:lang="ru"><p>115478 Москва, Каширское шоссе, 24</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0183-4827</contrib-id><name-alternatives><name xml:lang="en"><surname>Zaderenko</surname><given-names>I. A.</given-names></name><name xml:lang="ru"><surname>Задеренко</surname><given-names>И. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Igor A. Zaderenko</p><p>24 Kashirskoe Shosse, Moscow 115478</p></bio><bio xml:lang="ru"><p>115478 Москва, Каширское шоссе, 24</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0058-0987</contrib-id><name-alternatives><name xml:lang="en"><surname>Kadagidze</surname><given-names>Z. G.</given-names></name><name xml:lang="ru"><surname>Кадагидзе</surname><given-names>З. Г.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Zaira G. Kadagidze</p><p>24 Kashirskoe Shosse, Moscow 115478</p></bio><bio xml:lang="ru"><p>115478 Москва, Каширское шоссе, 24</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н. Н. Блохина» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2022-07-26" publication-format="electronic"><day>26</day><month>07</month><year>2022</year></pub-date><volume>21</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>47</fpage><lpage>55</lpage><history><date date-type="received" iso-8601-date="2022-07-26"><day>26</day><month>07</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-07-26"><day>26</day><month>07</month><year>2022</year></date></history><permissions><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://bioterapevt.abvpress.ru/jour/article/view/1327">https://bioterapevt.abvpress.ru/jour/article/view/1327</self-uri><abstract xml:lang="en"><p><bold>Background</bold>. The incidence of oral mucosa cancer (OMC) is higher in people over 50 years of age, and the aggressiveness of the course of the disease is higher in people under 50 years of age. In this context, it is of interest to clarify the mechanisms of immune disorders characteristic of patients of different age groups.</p><p><bold>Aim</bold>. To research systemic and local immunity in OMC patients and the relationship of peripheral blood lymphocyte population (PBLs) and tumor infiltrating lymphocytes (TILs) with the patient’s sex and age.</p><p><bold>Materials and methods</bold>. PBLs and TILs effector and suppressor populations were studied by flow cytometry in OMC patients aged 29 to 84 years.</p><p><bold>Results</bold>. The percentage of CD3<sup>-</sup>, CD3<sup>+</sup>CD4<sup>+</sup> and CD3<sup>+</sup>CD8<sup>+</sup>T cells, regulatory CD4<sup>+</sup>CD25<sup>+</sup>CD127<sup>low</sup><sup>/ –</sup>(CD4Treg) and CD8<sup>+</sup>CD11b<sup>–</sup>CD28<sup>–</sup>(CD8Тreg) T lymphocytes, CD4<sup>+</sup>PD-1<sup>+</sup> and CD8<sup>+</sup>PD-1<sup>+</sup> T cells was increased in TILs compared to PBLs. The levels of cytotoxic CD8<sup>+</sup>CD11b<sup>+</sup>CD28<sup>–</sup> T lymphocytes, NK, CD8<sup>+</sup>Perforin<sup>+</sup> and CD16<sup>+</sup>Perforin<sup>+</sup> cells in TILs were lower than in PBLs. The relationship between the level of CD4Treg and other TILs and PBLs depended on the patient’s sex. Age-related changes in the levels of NK and CD8 T-cells were observed in men, and CD4Treg – in women.</p><p><bold>Conclusion</bold>. Local immunity in OMC patients is highly immunosuppressive. The sex of patients influences the relationship between CD4Treg and other populations of PBLs and TILs, as well as age-related changes in the OMC patients’ immune system. This investigation results can make a certain contribution to personalized treatment of patients with OMC, taking into account differences in systemic and local immunity and in the immune response to the tumor in patients of different sex and age.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение</bold>. Частота развития рака слизистой оболочки полости рта (РСОПР) выше у лиц старше 50 лет, а агрессивность течения заболевания выше у лиц младше 50 лет. В этом контексте представляет интерес выяснение механизмов иммунных нарушений, характерных для пациентов различных возрастных групп.</p><p><bold>Цель исследования</bold> – провести сравнительное исследование системного и локального иммунитета у больных РСОПР, изучить взаимосвязь субпопуляционного состава лимфоцитов периферической крови (ПК) и лимфоцитов, инфильтрирующих опухоль (tumor infiltrating lymphocytes, TILs), с полом и возрастом пациентов.</p><p><bold>Материалы и методы</bold>. В исследование были включены пациенты в возрасте от 29 до 84 лет. Методом проточной цитометрии исследовали эффекторные и супрессорные популяции лимфоцитов ПК и TILs.</p><p><bold>Результаты</bold>. У больных РСОПР в опухолевой ткани по сравнению с ПК было повышено процентное содержание CD3<sup>-</sup>, CD3<sup>+</sup>CD4<sup>+</sup>- и CD3<sup>+</sup>CD8<sup>+</sup>-Т-клеток, регуляторных CD4<sup>+</sup>CD25<sup>+</sup>CD127<sup>low</sup><sup>/ –</sup>(CD4Трег) и CD8<sup>+</sup>CD11b<sup>–</sup>CD28<sup>–</sup> (CD8Трег) Т-лимфоцитов, а также CD4- и CD8<sup>+</sup>-Т-клеток, экспрессирующих коингибиторный рецептор PD-1. Уровни цитотоксических CD8<sup>+</sup>CD11b<sup>+</sup>CD28<sup>–</sup>-Т-лимфоцитов и CD8<sup>+</sup>Perforin<sup>+</sup>-клеток, цитотоксический потенциал CD8-Т-клеток, процент NK-клеток, включая CD16<sup>+</sup>Perforin<sup>+</sup>-популяцию, в опухоли были ниже, чем в ПК. Характер взаимосвязи уровня CD4Трег с другими популяциями лимфоцитов ПК и TILs зависел от пола пациентов. Возрастные изменения уровней NK- и CD8-T-клеток наблюдались главным образом у мужчин, а CD4Трег – у женщин.</p><p><bold>Заключение</bold>. Полученные данные подтверждают выраженное супрессивное состояние локального иммунитета у больных РСОПР. Пол пациентов влияет на характер взаимосвязи CD4Трег с другими популяциями лимфоцитов ПК и TILs, а также на возрастные изменения в иммунной системе пациентов с РСОПР. Результаты данного исследования могут внести определенный вклад в обеспечение персонализированного лечения больных РСОПР с учетом различий в системном и локальном иммунитете и в иммунном ответе на опухоль у больных разного пола и возраста.</p></trans-abstract><kwd-group xml:lang="en"><kwd>peripheral blood lymphocytes</kwd><kwd>TILs</kwd><kwd>CD4Treg lymphocytes</kwd><kwd>CD4<sup>+</sup>PD-1<sup>+</sup> and CD8<sup>+</sup>PD-1<sup>+</sup> lymphocytes</kwd><kwd>patients gender</kwd><kwd>patients age</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>лимфоциты периферической крови</kwd><kwd>TILs</kwd><kwd>CD4Трег лимфоциты</kwd><kwd>CD4<sup>+</sup>PD-1<sup>+</sup>- и CD8<sup>+</sup>PD-1<sup>+</sup>-лимфоциты</kwd><kwd>пол пациентов</kwd><kwd>возраст пациентов</kwd></kwd-group><funding-group><funding-statement xml:lang="en">The study was performed with the financial support of the Ministry of Health of Russian Federation in the framework of research No. ААА-А-А19-119022090028-6.</funding-statement><funding-statement xml:lang="ru">Исследование проведено при финансовой поддержке Министерства здравоохранения Российской Федерации в рамках темы НИР № ААА-А-А19-119022090028-6.</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Dhanuthai K., Rojanawatsirivej S., Thosaporn W. et al. Oral cancer: a multicenter study. Med Oral Patol Oral Cir Bucal 2018;23(1):e23–e9. DOI: 10.4317/medoral.21999</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Yokota T., Homma A., Kiyota N. et al. Head and neck cancer study group. Immunotherapy for squamous cell carcinoma of the head and neck. Jpn J Clin Oncol 2020;50(10):1089–96. DOI: 10.1093/jjco/hyaa139</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Deng W.W., Li Y.C., Ma S.R. et al. Specific blockade CD73 alters the “exhausted” phenotype of T cells in head and neck squamous cell carcinoma. Int J Cancer 2018;143(6):1494–504. DOI: 10.1002/ijc.31534</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Fenoglio D., Belgioia L., Parodi A. et al. Development of exhaustion and acquisition of regulatory function by infiltrating CD8+ CD28 – T Lymphocytes dictate clinical outcome in head and neck cancer. Cancers (Basel) 2021;13(9):2234. DOI: 10.3390/cancers13092234</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Chen J., Yang J., Li H. Single-cell transcriptomics reveal the intratumoral landscape of infiltrated T-cell subpopulations in oral squamous cell carcinoma. Mol Oncol 2021;5(4):866–86. DOI: 10.1002/1878-0261.12910</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Cohen E.E.W., Soulières D., Le Tourneau C. et al. KEYNOTE-040 investigators. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 2019;393(10167):156–67. DOI: 10.1016/S0140-6736(18)31999-8</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Johnson D.E., Burtness B., Leemans C.R. et al. Head and neck squamous cell carcinoma. Nat Rev Dis Primers 2020;6(1):92. DOI: 10.1038/s41572-020-00224-3</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Raskov H., Orhan A., Christensen J.P., Gögenur I. Cytotoxic CD8 + T cells in cancer and cancer immunotherapy. Br J Cancer 2021;124(2):359–67. DOI: 10.1038/s41416-020-01048-4</mixed-citation></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Zabotina T.N., Korotkova O.V., Borunova A.A. et al. Multiparameter study of the immunophenotype of lymphocytes infiltrating the tumor in cancer patients. Rossiiskiy onkologicheskiy zhurnal = Russian Journal of Oncology 2016;21(1–2):51–4. (In Russ.). DOI: 10.18821/1028-9984-2015-21-1-51-54</mixed-citation><mixed-citation xml:lang="ru">Заботина Т.Н., Короткова О.В., Борунова А.А. и др. Многопараметровое исследование иммунофенотипа лимфоцитов, инфильтрирующих опухоль у онкологических больных. Российский онкологический журнал 2016;21(1–2):51–4. DOI: 10.18821/1028-9984-2015-21-1-51-54</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Zabotina T.N., Chertkova A.I., Tsiklauri V.T. et al. Features of peripheral blood lymphocytes and tumor infiltrating lymphocytes subpopulations in patients with squamous cell head and neck cancer. Immunologiya = Immunology 2019;40(3):10–9. (In Russ.). DOI: 10.24411/0206-4952-2019-13002</mixed-citation><mixed-citation xml:lang="ru">Заботина Т.Н., Черткова А.И., Циклаури В.Т. и др. Особенности субпопуляционного состава лимфоцитов периферической крови и инфильтрирующих опухоль у больных плоскоклеточным раком головы и шеи. Иммунология 2019;40(3):10–9. DOI: 10.24411/0206-4952-2019-13002</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Zabotina T.N., Chertkova A.I., Borunova A.A. et al. Relationship of lymphocyte subpopulations in breast cancer patients with treatment results. Rossiyskiy bioterapevticheskiy zhurnal = Russian Journal of Biotherapy 2021;20(3):25–33. (In Russ.). DOI: 10.17650/1726-9784-2021-20-3-25</mixed-citation><mixed-citation xml:lang="ru">Заботина Т.Н., Черткова А.И., Борунова А.А. и др. Взаимосвязь субпопуляций лимфоцитов больных раком молочной железы с результатами лечения. Российский биотерапевтический журнал 2021;20(3):25–33. DOI: 10.17650/1726-9784-2021-20-3-25</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><mixed-citation>Zhao Y., Shao Q., Peng G. Exhaustion and senescence: two crucial dysfunctional states of T cells in the tumor microenvironment. Cell Mol Immunol 2020;17(1):27–35. DOI: 10.1038/s41423-019-0344-8</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Wherry E.J., Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol 2015;15(8):486–99. DOI: 10.1038/nri3862</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Davoodzadeh Gholami M., Kardar G.A., Saeedi Y. et al. Exhaustion of T lymphocytes in the tumor microenvironment: significance and effective mechanisms. Cell Immunol 2017;322:1–14. DOI: 10.1016/j.cellimm.2017.10.002</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Yang F., Zeng Z., Li J., Ren X., Wei F. IM-3 and CEACAM1 are prognostic factors in head and neck squamous cell carcinoma. Front Mol Biosci 2021;8:619765. DOI: 10.3389/fmolb.2021.619765</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Kurachi M. CD8(+) T cell exhaustion. Semin Immunopathol 2019;41(3):327–37. DOI: 10.1007/s00281-019-00744-5</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Jiang W., He Y., He W. et al. Exhausted CD8 + T cells in the tumor immune microenvironment: new pathways to therapy. Front Immunol 2021;11:622509. DOI: 10.3389/fimmu.2020.622509</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Zhang C., Liu Y. Targeting NK cell checkpoint receptors or molecules for cancer immunotherapy. Front Immunol 2020;11:1295. DOI: 10.3389/fimmu.2020.01295</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Penaloza-MacMaster P., Kamphorst A.O., Wieland A. et al. Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection. J Exp Med 2014;211(9):1905–18. DOI: 10.1084/jem.20132577</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Pawelec G. Does patient age influence anti-cancer immunity? Semin Immunopathol 2019;41(1):125–31. DOI: 10.1007/s00281-018-0697-6</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Irelli A., Sirufo M.M., D’Ugo C. et al. Sex and gender influences on cancer immunotherapy response. Biomedicines 2020;8(7):232. DOI: 10.3390/biomedicines8070232</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Henson S.M., Riddell N.E., Akbar A.N. Properties of end-stage human T cells defined by CD45RA re-expression. Curr Opin Immunol 2012;24(4):476–81. DOI: 10.1016/j.coi.2012.04.001</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Mirandola L., Wade R., Verma R. et al. Sex-driven differences in immunological responses: challenges and opportunities for the immunotherapies of the third millennium. Int Rev Immunol 2015;34(2):134–42. DOI: 10.3109/08830185.2015.1018417</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Gubbels Bupp M.R., Potluri T., Fink A.L., Klein S.L. The confluence of sex hormones and aging on immunity. Front Immunol 2018;9:1269. DOI: 10.3389/fimmu.2018.01269</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Capone I., Marchetti P., Ascierto P.A. et al. Sexual dimorphism of immune responses: a new perspective in cancer immunotherapy. Front Immunol 2018;9:552. DOI: 10.3389/fimmu.2018.00552</mixed-citation></ref></ref-list></back></article>
